bit.bio Introduces ioTracker Cells - New Innovation Enhancing Human Cell Visualization

bit.bio Launches a New Era of Cell Analysis with ioTracker Cells

At the forefront of biotechnology, bit.bio has just launched its innovative ioTracker cells at the Society for Laboratory Automation and Screening (SLAS) 2025 conference in San Diego. This new product range aims to enhance the tracking and isolation of human induced pluripotent stem cell (iPSC)-derived cells, providing researchers with unprecedented capabilities in understanding and addressing neurodegenerative diseases.

Revolutionizing Research with Nature-Derived Properties

The ioTracker cells build upon bit.bio’s acclaimed ioCells portfolio, infusing added visualisation functionalities powered by the company’s proprietary opti-ox™ technology. The first offering from this range, GFP ioMicroglia, is designed specifically to facilitate in-depth studies of microglial behavior in diverse experimental settings. Microglia, the brain's primary immune cells, play critical roles in responding to disease and injury, making them essential for research into conditions like Alzheimer's and Parkinson's disease.

This fresh approach promises to advance drug discovery workflows, as the GFP ioMicroglia retain the functionality, consistency, and defined characteristics that bit.bio is renowned for in the scientific community.

Key Features and Applications

As researchers navigate the complexities of the human brain, the ioTracker cells allow for real-time tracking of cell interactions in in vitro environments, which is crucial for studying neuroinflammation and neurodegenerative processes. This increased visibility into cellular dynamics will aid in deciphering the intricate behaviors of microglia, particularly their movement patterns and activation responses during various brain pathologies.

Mark Kotter, the Founder of bit.bio, emphasizes the new range’s potential: "With GFP ioMicroglia, we’re simplifying cell visualisation in complex model systems. Our commitment to innovation allows scientists to uncover details of human biology that were previously obscured."

Conference Showcase and Expert Discussions

bit.bio has positioned itself as a leader in cell programming technology since its inception. The company’s participation at SLAS 2025 serves not only to exhibit its cell offerings but also to engage in a series of poster sessions and panel discussions that spotlight the transformational role of their products in drug discovery.

Researchers visiting Booth #851 can interact with bit.bio's scientists and get insights into how ioTracker cells are reshaping the landscape of biomedical research. This hands-on approach exemplifies how bit.bio is committed to bridging the gap between cutting-edge science and practical research applications.

Commitment to Accessibility

Under Jonathan Milner’s leadership, bit.bio’s ethos revolves around making complex cellular tools readily available global for scientists aiming to tackle pressing health challenges. “With ioTracker cells, we empower researchers globally. Our mission is to deliver transformative research instruments that can facilitate groundbreaking discoveries in understanding and treating disabling neurological disorders,” Milner stated.

A Comprehensive Product Line

The ioCells line by bit.bio now boasts 46 distinct products that include ioWild Type Cells, ioDisease Model Cells, and ioCRISPR-Ready Cells, alongside the newly launched ioTracker cells. Each product is a testament to rigorous development, ensuring unparalleled consistency and functionality to advance scientific inquiry.

Looking Ahead: The Future of Neuroscience Tools

Farah Patell-Socha, the Vice President of Products at bit.bio, notes, “These cells offer researchers a refined approach for studying crucial processes associated with neuroinflammation and neurogenesis. By enabling accurate tracking within complex models, we facilitate a deeper understanding of intercellular dynamics in diseases.”

As bit.bio continues to innovate with products like GFP ioMicroglia, the future of cellular research looks promising. Their ongoing quest for excellence in biomedical research tools underscores a commitment to accelerating the discovery and eventual treatment of neurological diseases. Researchers interested in exploring the capabilities of bit.bio’s ioCells can access their extensive product catalogue online, with shipping options available worldwide.

About bit.bio

Founded in 2016 following a spin-out from the University of Cambridge, bit.bio revolutionizes how human cells are manufactured for drug discovery and biomedical research. With substantial backing from leading investors, the company strives to convert any iPSC into desired cell types using advanced programming technologies, thereby enhancing the research landscape aimed at transforming human health.